Infertility. Female infertility
Conditions
Interventions
Intervention 1: Control group one (group A)
10 people received 50 mg of intramuscular progesterone ampoule once a day/ Fertigest ampoule, Aburihan Company, Iran/50 mg). Intervention 2: Control group two (C) includes 10 people who received 400 m
Actoverco pharmaceutical company, Iran. Intervention 3: Intervention group: one is the B group in which 10 people received oral dydrogesterone 40 (Dofamed) mg per day
Atipharmed Company, Iran.
Sponsors
Research Vice President of Imam Khomeini Hospital Complex - Tehran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: Age between 20 and 40 years Women with normal endometrial thickness (8 mm or more) in the stage of endometrial preparation Body mass index below 30 kilograms per square meter FSH less than 15 Having less than 3 times entering the ART cycle Not having structural problems of the uterus (normal anatomy)
Exclusion criteria
Exclusion criteria: Having intrauterine pathologies such as polyps or submucosal myoma Intramural myoma above 3 cm Stage 3 or 4 endometriosis Untreated hydrosalpinx History of ovarian hyperstimulation syndrome Those who are candidates for embryo donation Genital Tuberculosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is clinical pregnancy rateand the continuation of pregnancy until 12 weeks. Timepoint: The presence of fetal heart rate in 6-7 weeks and continued pregnancy up to 12 weeks. Method of measurement: With transvaginal ultrasound. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes of chemical pregnancy rate. Timepoint: Positive BHCG level after two weeks of embryo transfer and a questionnaire filled by the therapist asking the patient. Method of measurement: Laboratory BHCG serum test and Questionnaire.;Abortion rate. Timepoint: BHCG level , transvaginal ultrasound and a questionnaire filled by the therapist asking the patient. Method of measurement: Laboratory BHCG serum test and questionnaire.;Ectopic pregnancy rate. Timepoint: Transvaginal ultrasound and a questionnaire filled by the therapist asking the patient. Method of measurement: Transvaginal ultrasound and questionnaire.;Presence of drugs complications such as drug sensitivity / vaginal burning and itching / muscle pain at the injection site / vaginal bleeding..etc..). Timepoint: A questionnaire filled by the therapist asking the patient after using the drugs. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHawraa Shbeeb
Tehran University of Medical Sciences
Outcome results
None listed